Matches in SemOpenAlex for { <https://semopenalex.org/work/W961745788> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W961745788 endingPage "82" @default.
- W961745788 startingPage "177" @default.
- W961745788 abstract "To evaluate the anti-tumor effect and toxicity of gemcitabine combined with platinum chemotherapy on recurrent epithelial ovarian cancer.Phase II study of gemcitabine combined with platinum chemotherapy was carried out in 22 patients with recurrent epithelial ovarian cancer. Median age of patients was 50.5 years old. Seven patients were platinum-sensitive and 15 patients were platinum-resistant or -refractory. All patients received gemcitabine combined with carboplatin or oxaliplatin chemotherapy. Patients' response rate (RR) and toxicity of gemcitabine combined with platinum chemotherapy were evaluated.A total of 98 gemcitabine-based chemotherapy cycles were performed. Total RR was 36.4%, RR of platinum-sensitive patients was 4/7 and platinum-resistant and -refractory patients was 4/15. The estimated median survival time was 10.0 months (95% CI: 7.0-13.0) after initiation of gemcitabine combined with platinum chemotherapy. There was no significant difference in survival time between platinum-resistant/refractory group and platinum-sensitive group (P = 0.061). Side effects of gemcitabine combined with platinum chemotherapy were observed in 81.8% of patients. Grade II/III anemia (54.5%) and grade III/IV neutropenia (54.5%) were most common toxicities. Ten (45.5%) patients had to delay their chemotherapy cycles or reduce the dose of chemotherapeutic drugs because of the severe side effects. Fourteen (63.6%) patients received granulocyte colony-stimulating factor to relieve neutropenia, and 8 (36.4%) patients received component blood transfusion to treat anemia or thrombocytopenia. There was no treat-ment-associated death.Gemcitabine combined with platinum chemotherapy appears to be an effective and well-tolerant treatment for recurrent epithelial ovarian cancer, including platinum-resistant or -refractory diseases." @default.
- W961745788 created "2016-06-24" @default.
- W961745788 creator A5014618105 @default.
- W961745788 creator A5036163975 @default.
- W961745788 creator A5042195058 @default.
- W961745788 creator A5042365149 @default.
- W961745788 creator A5059185619 @default.
- W961745788 creator A5061332222 @default.
- W961745788 creator A5068588368 @default.
- W961745788 date "2007-09-01" @default.
- W961745788 modified "2023-09-26" @default.
- W961745788 title "Phase II study of gemcitabine combined with platinum chemotherapy for recurrent epithelial ovarian cancer." @default.
- W961745788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17966166" @default.
- W961745788 hasPublicationYear "2007" @default.
- W961745788 type Work @default.
- W961745788 sameAs 961745788 @default.
- W961745788 citedByCount "0" @default.
- W961745788 crossrefType "journal-article" @default.
- W961745788 hasAuthorship W961745788A5014618105 @default.
- W961745788 hasAuthorship W961745788A5036163975 @default.
- W961745788 hasAuthorship W961745788A5042195058 @default.
- W961745788 hasAuthorship W961745788A5042365149 @default.
- W961745788 hasAuthorship W961745788A5059185619 @default.
- W961745788 hasAuthorship W961745788A5061332222 @default.
- W961745788 hasAuthorship W961745788A5068588368 @default.
- W961745788 hasConcept C121608353 @default.
- W961745788 hasConcept C126322002 @default.
- W961745788 hasConcept C141071460 @default.
- W961745788 hasConcept C143998085 @default.
- W961745788 hasConcept C2776694085 @default.
- W961745788 hasConcept C2777063308 @default.
- W961745788 hasConcept C2778239845 @default.
- W961745788 hasConcept C2780258809 @default.
- W961745788 hasConcept C2780427987 @default.
- W961745788 hasConcept C2780962732 @default.
- W961745788 hasConcept C2781451048 @default.
- W961745788 hasConcept C526805850 @default.
- W961745788 hasConcept C71924100 @default.
- W961745788 hasConcept C90924648 @default.
- W961745788 hasConceptScore W961745788C121608353 @default.
- W961745788 hasConceptScore W961745788C126322002 @default.
- W961745788 hasConceptScore W961745788C141071460 @default.
- W961745788 hasConceptScore W961745788C143998085 @default.
- W961745788 hasConceptScore W961745788C2776694085 @default.
- W961745788 hasConceptScore W961745788C2777063308 @default.
- W961745788 hasConceptScore W961745788C2778239845 @default.
- W961745788 hasConceptScore W961745788C2780258809 @default.
- W961745788 hasConceptScore W961745788C2780427987 @default.
- W961745788 hasConceptScore W961745788C2780962732 @default.
- W961745788 hasConceptScore W961745788C2781451048 @default.
- W961745788 hasConceptScore W961745788C526805850 @default.
- W961745788 hasConceptScore W961745788C71924100 @default.
- W961745788 hasConceptScore W961745788C90924648 @default.
- W961745788 hasIssue "3" @default.
- W961745788 hasLocation W9617457881 @default.
- W961745788 hasOpenAccess W961745788 @default.
- W961745788 hasPrimaryLocation W9617457881 @default.
- W961745788 hasVolume "22" @default.
- W961745788 isParatext "false" @default.
- W961745788 isRetracted "false" @default.
- W961745788 magId "961745788" @default.
- W961745788 workType "article" @default.